GRAIL, Inc. Common Stock
GRALGRAIL, Inc. is a healthcare company focused on developing early detection tests for cancer and other life-threatening diseases using advanced genomic sequencing and data science. Founded with the goal of transforming cancer detection through blood tests, GRAIL leverages large-scale genomic research and machine learning to identify molecular markers associated with various cancers, aiming to enable earlier diagnosis and improve patient outcomes.
Company News
Rosen Law Firm has filed class action lawsuits against Intuit Inc., GRAIL Inc., and Genius Group Limited on behalf of investors who purchased securities during specified periods. The lawsuit against Intuit alleges the company made materially false statements about its competitive advantages and overstated TurboTax revenue growth guidance, while t...
A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri trial results. The company allegedly concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025...
Rosen Law Firm has filed securities class action lawsuits against Zillow Group, Intuit Inc., and GRAIL Inc., alleging materially false and misleading statements. For Zillow specifically, the lawsuit claims the company mischaracterized its Redfin agreement and downplayed antitrust regulatory risks. Investors who purchased shares during specified c...
Rosen Law Firm has filed securities class action lawsuits against BitGo Holdings, Intuit Inc., and GRAIL, Inc., alleging that offering documents contained materially false and misleading statements. BitGo is accused of understating risks related to declining digital asset prices. Investors who purchased securities during specified class periods a...
Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 bi...
Related Companies
